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ZK 36·374, a Stable Analog of Prostacyclin, Prevents Acute Hypoxic
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E. KENNETH WEIR, MD, FACC
Minneapolis, Minnesota
Vasodilator therapy in pulmonary hypertension is lim-
ited by the lack of an agent selectivefor the pulmonary
circulation. The effects of intravenous prostacyclin and
two stable prostaglandin analogs, ZK 36-374 and CL
115,347, were assessed on the preconstricted pulmonary
vasculature of the anesthetized dog. During hypoxic va-
soconstriction ZK 36-374 (0.4 JLg/kg per min) markedly
reduced pulmonary artery pressure (26 ± 3 to 13 ± I :
mm Hg) (p < 0.05) and pulmonary vascular resistance
(6.2 ± 1.1 to 2.8 ± 0.2 mm Hglliter per min) (p <
0.01). There was no significant effect on cardiac output,
aortic pressure or arterial blood gases. Pulmonary va-
soconstriction induced by prostaglandin F20! was sim-
ilarly affected by ZK 36-374, and in this instance the
aortic pressure was also reduced (158 ± 11 to 129 ±
11 mm Hg) (p < 0.01).
ZK 36-374 (0.2 JLglkg per min) was more effectivein
Pulmonary hypertension may complicate the management
of a variety of cardiopulmonary disorders such as chronic
obstructive airways disease, mitral valve disease, left heart
failure, thromboembolic disease and left to right intracardiac
shunts , or it may occur in isolation (primary pulmonary
hypertension) . The relative importance of fixed vascular
obstruction and vasoconstriction varies with the type and
duration of the underlying disease. In some forms of pul-
monary hypertension, mechanical obstruction is amenable
to surgical correction (for example, mitral valve replacement
or pulmonary thromboendarterectomy). However, in most
cases the only therapeutic interventions available are anti-
coagulation, or the use of oxygen or vasodilator agents. The
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lowering hypoxic pulmonary vascular resistance (from
6.5 ± 0.6 to 3.0 ± 0.3 mm HglIiter per min) than was
prostacyclin (0.75 JLg/kg per min) (from 6.3 ± 0.6 to
4.2 ± 0.4 mm Hg/liter per min) (p < 0.05) and resulted
in a smaller fall in aortic pressure (p < 0.05). CL 115,347
(1.0 JLg/kg per min) had no effect on the pulmonary
vasculature during normoxia or when preconstricted by
prostaglandin F20! or hypoxia, but reduced aortic pres-
sure and total systemic resistance (p < 0.05). It appears
to be a selectivesystemic vasodilator with no pulmonary
vascular activity.
ZK 36-374 is an effective agent in reversing pulmo-
nary vasoconstriction in this model and has potentially
useful selectivity for the pulmonary circulation. Oral
administration is possible.
(J Am Coli CardioI1986;8:1189-94)
use of vasodilators in patients with pulmonary hypertension
has been limited by the lack of an orally active agent that
is selective for the pulmonary vasculature. Nonselective
vasodilators used in the presence of a fixed pulmonary vas-
cular resistance may result in systemic vasodilation, which
is not offset by an increase in cardiac output and can thus
cause systemic hypoten sion .
This study compares the relative selectivity of prosta-
cyelin and two novel prostaglandin analogs on the pulmo-
nary and systemic vasculatures. The short half-life of in-
travenous prostacyelin makes it useful in assessing the
reversible component of pulmonary hypertension, by re-
ducing the risk of prolonged systemic hypotension. Unfor-
tunately, the short half-life, lack of relative selectivity for
the pulmonary vasculature and absence of an oral form of
prostacyclin prevent its use for long-term treatment. ZK 36-
374, a stable carbaprostacyelin analog of prostacyelin , has
hemodynamic properties similar to those of the parent com-
pound but can be given orally and has a significantly in-
creased half-life (l,2). CL 115, 347 is a methyl ester of 15-
deoxy-16-hydroxy- I6-(a/I3)-vinyl prostaglandin E2 , which
is vasoactive and can be administered orally or topically
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(3). The efficacy of these agents was tested in the model of
pulmonary hypertension provided by hypoxia and prosta-
glandin Fza-induced pulmonary vasoconstriction in the
anesthetized dog.
Methods
Experimental procedures. Twenty mongrel dogs of either
sex were anesthetized with sodium pentobarbital (30 mg/kg
intravenously), paralyzed with succinyl choline (2 mg/kg
intravenously) and ventilated with a Harvard ventilator. A
Swan-Ganz catheter was advanced into the pulmonary ar-
tery. Two cannulas were placed in the descending aorta and
one was placed in the inferior vena cava.
Body temperature was monitored by an esophageal tem-
perature probe (model 43T A, Yellowsprings Instrument
Company) and was maintained between 37 and 39°C. Blood
pressure was recorded using a Statham P23 transducer con-
nected to a Hewlett Packard 8 channel recorder. Cardiac
output was measured by injecting 1 ml of indocyanine green
dye (Eastman Kodak) (1.25 mg/ml) into the inferior vena
cava and withdrawing blood from the aortic catheter (20 mll
min) through a cuvette densitometer connected to a cardiac
output computer (Waters Instrument). Arterial blood gases
were measured using a Coming model 168 pH and blood
gas analyzer.
Figure 1. Schematic representation of experimental protocols 1
and 2. *Hemodynamics and arterialbloodgasesmeasured; hypoxia
= period of ventilationwith FiOz0.1. The broken line along the
time axis reflects the fact that only six dogs received more than
one drug (see protocol 1 in Methods).
Before the experiment an equilibration period was used
to establish the appropriate respiratory rate and tidal volume
to maintain arterial partial pressure of carbon dioxide (Pco-)
in the range of 35 to 45 mm Hg. The rate and volume were
left unchanged during the remainder of the experiment.
Drugs. Prostacyclin (Sigma), CL 115,347 (American
Cyanamid Company) and ZK 36-374 (Schering), were pre-
pared immediately before use by diluting the stock solution
with 0.9% saline.
Protocol
Protocol 1. Preliminary experiments were performed to
determine doses of each drug that would have significant
hemodynamic effects during hypoxia but not induce unac-
ceptable hypotension. The intravenous doses selected were
ZK 36-374 (0.2 jLg/kgper min X 7 min), prostacyclin (0.75
jLg/kg per min for 7 minutes), and CL 115, 347 (1.0 jLg/kg
per min for 7 min).
After an initial equilibration period, pulmonary vaso-
constriction was induced by ventilation with an hypoxic
mixture (concentration of expired oxygen in air [FiOz] 0.1)
(Fig. 1). Hemodynamic variables and arterial blood gases
were recorded at the end of the normoxic control period and
after 8 and 15 minutes of hypoxia. After a further 15 minute
normoxic control period another hypoxic challenge was given
but this time the drug to be tested was infused during the
final 7 minutes of the hypoxic period. Hemodynamic vari-
able and arterial blood gases were measured as before. The
drugs were tested in 14 dogs: 6 dogs received CL 115,347
only, 2 dogs received ZK 36-374 only and 6 dogs received
ZK 36-374 and prostacyclin. In animals receiving two drugs
the order of administration was randomized and hemody-
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Results
Protocol J (Table J)
Hypoxia elevated the pulmonary artery pressure and re-
sistance at both 8 and 15 minutes of hypoxia (p < 0.05 for
both). There were no significant differences between the 8
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Figure 2. ZK 36-374 lowers pulmonary artery pressure and vas-
cular resistance more than prostacyclin during hypoxic pulmonary
vasoconstriction (protocol 1). *p < 0.05: value differs from pre-
drug hypoxic value; tp < 0.05: value obtained during infusion of
ZK 36-374 (0.2 jLg/kgper min) differs from value obtained during
infusion of prostacyclin (0.75 jLg/kg per min). Hypoxia = period
of ventilation with FiOz 0.1.
namic variables were allowed to return to baseline over 30
minutes before the control hypoxic challenge was repeated.
Protocol 2. Protocol 1 demonstrated that CL 115,347
had no activity on the pulmonary vasculature preconstricted
by hypoxia and no further testing was performed. ZK 36-
374 was tested in six dogs by a second protocol to determine
whether its longer half-life would allow infusion of the drugs
before a hypoxic challenge and diminish the undesired drop
in aortic pressure noted in protocol 1, while still reducing
the hypoxic pulmonary hypertension. As before, an initial
normoxic control period was followed by a 15 minute hy-
poxic challenge (FiO z0.1) (Fig. 1). Hemodynamic variables
and arterial blood gases were measured as in protocol 1.
The only drug tested in this protocol was ZK 36-374 (0.4
j.Lg/kg per min intravenously), which was given over the 5
minutes before the next hypoxic period. For comparison
with the observations made during hypoxic pulmonary va-
soconstriction, protocol 2 also tested ZK 36-374 against
pulmonary vasoconstriction induced by prostaglandin FzO'
(5j.Lg/kg per min intravenously, for 4 minutes). Hemody-
namic variables and arterial blood gases were measured as
shown in Figure 1.
Statistical Methods. All values are expressed as mean
± SEM. Intergroup comparisons were made using analysis
of variance. Subsequent post hoc analysis was made using
Tukey's test. When only two groups were compared, a
Student's t test was used. Probability values of less than
0.05 were considered statistically significant.
Table 1. Effects of Intravenous Infusion of ZK 36-374, Prostacyclin and CL 115,347 (given by protocol 1) on Hemodynamics
During Hypoxia
Mean
Mean Aortic Pulmonary Cardiac Total Systemic Pulmonary Vascular Arterial Oxygen
Pressure Artery Pressure Output Resistance Resistance Tension
(mm Hg) (mmHg) (liters/min) (mm Hg/liter per min) (mm Hg/liter per min) (rnm Hg)
Normoxia 144 ± 5 13 ± 3.0 ± 0.4 51 ± 5 2.8 ± 0.2 88 ± 4.0
Hypoxia, 8 min 173 ± 6 26 ± 3.4 ± 0.3 54 ± 4 6.2 ± 0.5 32 ± 1
Hypoxia, 15 min 170 ± 6 24 ± 3.5 ± 0.3 52 ± 4 5.7 ± 0.4 30 ± 2
Normoxia 143 ± 4 13 ± 1 3.0 ± 0.5 53 ± 5 3.0 ± 0.3 100 ± 1
Hypnxia, 8 min 171 ± 5 26 ± 1 3.5 ± 0.4 59 ± 6 6.5 ± 0.6 34 ± 1
Hypnxia, 15 mini 137 ± 7*·t 15 ± 1* 3.4 ± 0.5 42 ± 4* 3.0 ± 0.3*·t 33 ± 2
ZK 36-374 per
(0.2 ILg/kg per min)
Normoxia 150 ± 6 14 ± I 3.1 ± 0.6 56 ± 8 3.1 ± 0.4 99 ± 3
Hypoxia, 8 min 177 ± 8 27 ± 1 3.6 ± 0.4 54 ± 6 6.3 ± 0.6 33 ± 2
Hypnxia, 15 mini 110 ± 19* 17 ± 2* 3.0 ± 0.3 38 ± 5* 4.2 ± 0.4* 33 ± 2
prostacyclin
(0.75 ILg/kg per min)
Normoxia 131 ± 4 12 ± I 3.5 ± 0.3 38 ± 3 2.5 ± 0.2 87 ± 4
Hypoxia, 8 min 152 ± 7 23 ± 3 3.5 ± 0.2 44 ± 2 5.5 ± 0.4 30 ± 2
Hypoxia, 15 mini 102 ± 5* 25 ± 2 3.7 ± 0.2 28 ± 2* 5.8 ± 0.4 31 ± 2
CL 115,347 per
(1.0 ILg/kg per min)
*p < 0.05, value differs from the 8 minute hypoxic value; tp < 0.05, value obtained during infusion of ZK 36-374 differs from that obtained during
infusion of prostacyclin. All values are expressed as the mean and SEM.
1192 ARCHERET AL.
ZK 36-374 PREVENTS HYPOXIC PULMONARY HYPERTENSION
JACC Vol. 8. No. 5
November 1986: 1189- 94
200
1180
!
; 160
•
•e
A. 140
.!!
1:
o
<C
c 120
:
2
100
o
.-. ZK 36-314 n - 6
0 · · · ·0 Proslaeye;in n - 6
~ Period of Drug Inluslon
I HYPOXIA i
15 30
Tim. (min)
70
:s
E 60
.....
oJ
.....
III
:z:! 50
•g 40
~
•ii
~ 30
u
E
; 20
,..
en
'ii
~ 10
o
HYPOXIA
15 30
Tim. (min)
with ZK 36-374 (0 .2 jLglkg per min) than with prostacyclin
at a higher dose (0.75 jLg/kg per min) (Fig. 2) despite the
fact that prostacyclin tended to lower the absolute mean
aortic pressure more than did ZK 36-374 (Fig. 3). In fact
the fall in aortic pressure after prostacyclin ( - 66 ± IS mm
Hg) was greater than that after ZK 36-374 ( - 34 ± 6 mm
Hg) (p < 0.05 ).
CL 115.347 had no effect on the pulmonary vascular
hemodynamics during hypoxia, nor did it alter cardiac out-
put , mean pulmonary wedge pressure or arterial blood gases.
It did lower the IS minutes hypoxic value for mean aortic
pressure compared with the 8 minute (pre-CL 115,347) hy-
poxic value (from 152 ± 7 to 102 ± 5 mm Hg) and also
lowered the total systemic resistance (from 44 ± 2 to
28 ± 2 mm Hg/liter per min) (p < 0.05 for each).
Figure 3. ZK 36-374 and prostacyclin reduce aortic pressure and
total sys te mi c resistance during hypoxi a (pro toc o l I).*p < 0.05:
value differs from hypoxic control value ; hyp oxia = period of
ventilat ion wi th FiOz 0.1.
and IS minute values for either mean pulmonary artery
pressure ' ~6 ± I and 24 ± I mm Hg, respectively) or
pulmona vascular resistance (6.2 ± 0.5 , and 5.7 ± 0.4
mill Hg/i.ter per min , respectively). The mean aortic pres-
sure was also elevated by hypoxia (p < 0.05 ), but the total
systemic resistance was not affected .
Infusion of ZK 36-374 (0 .2 uglkg per min) or prosta-
eye/in (0.75 uglkg per min) during the final 7 minutes of
the hypoxic period lowered the mean aortic pressure , total
systemic resistance, mean pulmonary artery pressure and
pulmonary vascular resistance measured after IS minutes
of hypoxia compared with the 8 minute hypoxic value (p <
0.05 for each). There were no effects on the cardiac out-
put , mean pulmonary wedge pressure or arterial blood
gases. The fall in pulmonary vascular resistance was greater
Protocol 2
Hypoxia (Table 2). As in protocol I , hypoxia alone
increased pulmonary artery pressure (from 14 ± I to
26 ± 3 mm Hg), pulmonary vascular resistance (from 3.1 ±
0 .3 to 6 .2 ± 1.1 mm Hglliter per min) and mean aortic
pressure (from 147 ± 5 to 172 ± 7 mm Hg) (p < 0.05
for each) compared with normoxic control values. Infusion
of ZK 36-374 (0.4 jLg/kg per min) during the 5 minutes
before hypoxia lowered mean aortic pressure and total sys-
temic resistance (p < 0.05 for each) without affecting car-
diac output , mean wedge pressure or arterial blood gases.
The infusion was stopped at the onset of hypoxia, and the
8 and IS minute hypoxic values were measured with no
drug infusion. At 8 and IS minutes of hypoxia the mean
pulmonary artery pressure and pulmonary vascular resist-
ance were decreased significantly compared with the pre-
ceding 8 and 15 minute hypoxic control values. In protocol
2 the mean aortic pressure , measured at 8 minutes of hy-
poxia, decreased slightly (from 172 ± 7 to ISO ± 7 mm
Hg) while the pulmonary vascular resistance returned to
Table 2. Pretreatment W ith ZK 36-374 Reduces Hypoxic Pulmon ary Vasoc on stricti on (pro toc o l 2)
Mean Total Systemic
Mean Aortic Pulmonary Mean Pulmonary Cardiac Resistance Pulmonary Vascular Arterial Oxygen
Pressure Artery Pressure Wedge Pressure Output (mm Hglliter Resistance (mm Hg/ Tension
(mm Hg) (mm Hg) (mm Hg) (liters/min) per min) liter per min) (mm Hg)
Normoxia 147 ± 5 14 ± I 5 ± 3.0 ± 0.4 53 ± 8 3. 1 ± 0.3 95 ± 2
Hypoxia, 8 min 172 ± 7 26 ± 3 5 ± 3.4 ± 0.4 52 ± 5 6.2 ± 1.1 32 ± I
Hypoxia, 15 min 165 ± 6 24 ± 2 5 ± 3.5 ± 0.3 49 ± 5 5.6 ± 0.8 28 ± I
Normoxic control 138 ± 6 13 ± I 4 ± 2.8 ± 0.4 54 ± 6 3.0 ± 0. 1 93 ±
5 Min post ZK 94 :!: 1O:j: II ± I 4 ± 2.9 ± 0.6 35 ± 3t 2.6 ± 0.2 96 ±
36-374
(0.4 J,lg/kg per min)
Hypoxia, 8 min 150 ± 7 13 ± It 4 ± I 2.9 ± 0.4 55 ± 6 2.8 ± 0 .2* 34 :!: 1
Hypoxia, 15 min 152 ± 6 16 ± 2* 5 ± I 3.4 ± 0.3 48 ± 5 3.4 ± 0.4* 30 ± I
*p < 0.05 , t p < 0.01 : value differs from the hypoxic control value: :j:p < 0.05 value obtained during infusion of ZK 36-374 differs from that
obtained during normoxic control period. All values are expressed as the mean ± SEM.
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Table 3. ZK 36-374 Reduces Prostaglandin F2a-Induced Pulmonary Vasoconstriction (protocol 2)
Mean Mean Cardiac Total Systemic
Mean Aortic Pulmonary Pulmonary Output Resistance Pulmonary Vascular Arterial Oxygen
Pressure Artery Pressure Wedge Pressure (liters! (mmHg/liter Resistance (mm Hgi Tension
(mmHg) (mmHg) (mmHg) min) per min) liter per min) (mmHg)
Normoxia 148 ± 6 13 ± I 5 ± I 3.0 ± 004 53 ± 8 2.7 ± 004 93 ± 2
PGF2a (5 p.glkg per min) 158 ± II 25 ± 3* 6 ± I 3.1 ± 004 54 ± 6 6.6 ± 1.1* 94 ± 2
Norrnoxia 134 ± 4 12 ± I 4 ± I 2.6 ± 004 58 ± 8 304 ± 0.2 95 ± 2
5 Min post ZK 36-374 97 ± 9t II ± I 4± 1 3.2 ± 0.7 33 :!: 4t 2.6 ± 0.2 96 ± I
(004 p.g!kg per min)
PGF2alZK 36-374 129 ± II§ 15 ± 2§ 4±1 2.6 ± 0.5 53 ± 7 4.3 ± OAt 88 ± 6
*p< 0.05: value obtained with PGF2a differs from the normoxic control value; t p < 0.01 : value followingZK 36-374 differs from normoxic control
value; tp < 0.05, §p < 0.01 : value following PGF2a plus ZK 36-374 differs from value following PGFla alone . All values are expressed as the mean
± SEM.
norrnoxic levels (from 6.2 ± 1.1 to 2.8 ± 0.2 mm Hg/liter
per min).
Prostaglandin F2a (Table 3). Prostaglandin F2a ele-
vated mean pulmonary artery pressure (from 13 ± 1 to 25
± 3 mm Hg) and pulmonary vascular resistance (from 2.7
± 0.4 to 6.6 ± 1.1 mm Hg/liter per min) (p < 0.05 for
each) without affecting cardiac output, mean wedge pres-
sure, mean aortic pressure, total systemic resistance or ar-
terial blood gases. After administration of ZK 36-374 (0.4
J-Lgikg per min), prostaglandin F2a caused a smaller rise in
mean pulmonary artery pressure (from 11 ± 1 to 15 ± 2
mm Hg) and pulmonary vascular resistance (from 2.6 ±
0.2 to 4.3 ± 0.4) (p < 0.01 and <0.05 , respectively).
Figure 4. ZK 36-374 (protocol 2) exerts a relatively greater va-
sodilatory effect onthepulmonary vasculature than onthesystemic
vasculature during hypoxia. Open bars represent the absolute
value after 15 minutes of hypoxia without drug. Hatched bars
represent the absolute value after 15 minutes of hypoxia when
preceded by infusion of ZK 36-374. *p< 0.05: value differs from
hypoxic control value.
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Discussion
The treatment of pulmonary hypertension by vasodilator
agents is frequently complicated by systemic hypotension
because no dilator selective for the pulmonary vasculature
is available. Prostacyclin is an endogenous vasodilator that
acts on the pulmonary circulation but has a half-life of only
3 minutes and requires intravenous administration (l,4).
ZK 36-374 is a more stable analog of prostacyclin and
has a half-life of 13 minutes when given intravenously (5) .
When given orally to rats it has a bioavailability of 13%
(6). Both prostacyclin and ZK 36-374 have been postulated
to cause vasodilation by binding to receptors in the arterial
wall (7) .
eL-IIS .347 is a prostglandin £ 2 analog with systemic
antihypertensive activity. It can be given by oral or topical
routes (3) . When given topically in rats it significantly low-
ers arterial pressure for 24 hours without inducing tachy-
cardia (3) .
Effect of ZK 36-374 on pulmonary hypertension. The
present studies show that ZK 36-374 causes a smaller re-
duction in systemic arterial pressure than does prostacyclin,
while producing a greater decrease in hypoxic pulmonary
vascular resistance in this model of pulmonary hypertension
(Fig. 4). ZK 36-374 reduced hypoxic pulmonaryartery pres-
sure and resistance to norrnoxic levels. The systemic arterial
oxygen tension at the end of 15 minutes of hypoxia was not
diminished by infusions of either ZK 36-374 or prostacyclin
in comparison with hypoxic control values. This suggests
that the vasodilation occurred without the increase in venous
shunting that has been noted after the use of other vasodi-
lators (8). Infusion of ZK 36-374 also diminished the pul-
monary hypertension induced by prostaglandin F2a . CL
115,374 showed selectivity for the systemic circulation in
that it reduced systemic arterial pressure and resistance,
while pulmonary vascular hemodynamic variables were un-
changed during hypoxia.
Previous clinical studies. ZK 36-374 has been used
clinically in patients with severe peripheral vascular disease
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(5). It was infused over 3 days (0.5 to 4.0 ng/kg per min
intravenously) . After about 24 hours aortic pressure had
decreased 15%, while pulmonary vascular resistance was
reduced by 34%. When the dose was increased to 8 ng/kg
per min, side effects such as headache , nausea and abdom-
inal pain occurred. One day after the end of the infusion,
pulmonary vascular resistance was still low in comparison
with the preinfusion level (5). ZK 36-374 has also been
shown to reduce platelet aggregation in humans , at a dose
(up to 2 ng/kg per min intravenously over 4 hours) , which
did not alter systemic arterial pressure or heart rate (9).
Implications. While ZK 36-374 is clearly not specific
for the pulmonary vasculature, it does represent an im-
provement in this respect when compared with prostacyclin.
The information derived from an acute experiment in healthy,
anesthetized dogs should not be directly extrapolated to the
long-term therapy of patient with pulmonary hypertension.
However, these results, the clinical information already ob-
tained on the infusion of ZK 36-374 in humans and the
availability of an oral form suggest that clinical trials of ZK
36-374 for the treatment of pulmonary hypertension may be
justified.
We are very grateful to M. Haberey, MD (Schering) and C.W. Mickiewicz ,
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115,347 , respectively , and to Vicki Hayle for preparation of the manu-
script.
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